High-throughput and in silico techniques in drug metabolism and pharmacokinetics

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 1, 2002, Pages 33-43

  Van de Waterbeemd, Han ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Automation; E ADME; High throughput ADME; In silico ADME; In vitro metabolism; Mass spectrometry; Pharmacokinetics

Indexed keywords

DRUG;

COMPUTER MODEL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; IN VITRO STUDY; MASS SPECTROMETRY; MEDICAL LITERATURE; MOLECULAR MODEL; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SCREENING; TECHNIQUE;

ABSORPTION; ANIMALS; AUTOMATION; CHEMISTRY, PHYSICAL; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036234783     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Property-based design: Optimization of drug absorption and pharmacokinetics
2. Current methodologies used for evaluation of intestinal permeability and absorption
3. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery
4. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics
5. Compound optimization in early- and late-phase drug discovery: Acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens
6. Rapid assessment of drug metabolism in the drug discovery process
7. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery
8. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery
9. ADME/PK as part of a rational approach to drug discovery
10. Pharmacokinetics and metabolism in early drug discovery
11. The use of kinetic and metabolic predictions in drug development
12. Rational high-throughput screening in preclinical drug metabolism
13. Managing the drug discovery/development interface
14. A scoring scheme for discriminating between drugs and non-drugs
15. Discriminating between drugs and non-drugs by prediction of activity spectra for substances (PASS)
16. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
17. Drug-like properties and the causes of poor solubility and poor permeability
18. Drug-like index: A new approach to measure drug-like compounds and their diversity
19. High-throughput high-performance liquid chromatography/mass spectrometry for modern drug discovery
20. A high-capacity LC/MS system for the bioanalysis of samples generated from plate-based metabolic screening
21. AutoScan: An automated workstation for rapid determination of mass and tandem mass spectrometry conditions for quantitative bioanalytical mass spectroscopy
22. High-speed HPLC/MS/MS analysis of biological fluids: A practical view
23. Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening
24. Flow NMR spectroscopy in drug discovery
25. Metabolic screening using online ultrafiltration mass spectrometry
26. Increasing bioanalytical throughput using pcSFC-MS/MS: 10 Minutes per 96-well plate
27. A clinical trial on a plate? The potential of 384-well format solid-phase extraction for high-throughput bioanalysis using liquid chromatography/ tandem mass spectrometry
28. pH-metric solubility. 2: Correlation between the acid-base titration and the saturation shake-flask solubility-pH methods
29. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates
30. Multi-wavelength spectrophotometric determination of acid dissociation constants: A validation study
31. a screening of pharmaceuticals by pressure-assisted capillary electrophoresis
32. An increased throughput method for the determination of partition coefficients
33. Chromatographic retention of drug molecules on immobilized liposomes prepared from egg phospholipids and from chemically pure phospholipids
34. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption
35. ElogPoct: A tool for lipophilicity determination in drug discovery
36. High-throughput liquid chromatography/mass spectrometry method for the determination of the chromatographic hydrophobicity index
37. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein
38. Evaluation of the BBMEC model for screening the CNS permeability of drugs
39. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity
40. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract
41. Comparison of passive drug transport through Caco-2 cells and artificial membranes
42. Physicochemical high-throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes
43. Physicochemical profiling (solubility, permeability, and charge state)
44. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes
45. SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: Correlation with fraction absorbed in humans
46. Lipophilicity in PK design: Methyl, ethyl, futile
47. Relation of molecular properties with absorption and drug disposition
48. Lipophilicity of metabolites and its role in biotransformation
49. Induced correlations in the use of unbound/intrinsic pharmacokinetic parameters in quantitative structure-pharmacokinetic relationships with lipophilicity
50. Early ADME in support of drug discovery: The role of metabolic stability studies
51. Screening for human ADME/Tox drug properties in drug discovery
52. Present and future in vitro approaches for drug metabolism
53. Predicting drug pharmacokinetics in humans from in vitro metabolism studies
54. The prediction of human clearance from hepatic microsomal metabolism data
55. Screening of drug candidates for their drug-drug interaction potential
56. Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery
57. EUFEPS conference report. Optimising drug development: Strategies to assess drug metabolism/transporter interaction potential towards a consensus
58. Higher-throughput screening with human cytochromes P450
59. Advances in in vitro drug metabolism screening
60. Fluorometric screening for metabolism-based drug-drug interactions
61. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential
62. Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies
63. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates
64. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy: III. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2C19 inhibition evaluation
65. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy II. Validation of a direct injection/online guard cartridge extraction-tandem mass spectrometry method for CYP2D6 inhibition assessment
66. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment
67. Higher throughput metabolite identification in drug discovery: Current capabilities and future trends
68. High-throughput pharmacokinetics: Cassette dosing
69. Use of 'N-in-one' dosing to create an in vitro pharmacokinetics database for use in developing structure-pharmacokinetic relationships
70. Pharmacokinetic theory of cassette dosing in drug discovery screening
71. Combining high-throughput pharmacokinetic screens at the hits-to-lead stage of drug discovery
72. Cassette-accelerated rapid rat screen: A systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery
73. High-throughput analysis in drug discovery: Application of liquid chromatography/ion-trap mass spectrometry for simultaneous cassette analysis of α-1a antagonists and their metabolites in mouse plasma
74. Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats
75. Development of a high-throughput equilibrium dialysis method
76. A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening
77. The role of transport proteins in drug absorption, distribution and excretion
78. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein
79. Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity
80. Structure-activity relationship studies of propafenone analogues based on P-glycoprotein ATPase activity measurements
81. Calcein accumulation as a fluorometric functional assay of the multidrug transporter
82. A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function
83. Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatography stationary phase
84. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells
85. Progress in predicting human ADME parameters in silico
86. Computational methods to estimate drug development parameters
87. Application of in silico approaches to predicting drug-drug interactions
88. Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: The need for quantitative databases
89. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions
90. The absolute oral bioavailability of selected drugs
91. The dynamics of drug absorption, distribution, and elimination
92. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors
93. QSAR model for drug human oral bioavailability
94. Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans
95. Effect of diverse datasets on the predictive capability of ADME models in drug discovery
96. Can the internet help to meet the challenges in ADME and e-ADME?
97. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach
98. Substructure and whole molecule approaches for calculating log P
99. Octanol-water partition: Searching for predictive models
100. Quantitative estimation of drug absorption in humans for passively transported compounds on the basis of their physico-chemical parameters
101. Experimental and computational screening models for the prediction of intestinal drug absorption
102. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
103. Estimation of aqueous solubility in drug design
104. Estimating the water solubilities of crystalline compounds from their chemical structures alone
105. Simultaneous prediction of aqueous solubility and octanol/water partition coefficient based on descriptors derived from molecular structure
106. Quantitative structure-absorption relationships
107. Theoretical calculation and prediction of drug transport processes using simple parameters and partial least squares projections to latent structures (PLS) statistics. The use of electrotopological state indices
108. Predicting oral drug absorption in humans
109. Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers
110. Theoretically-derived molecular descriptors important in human intestinal absorption
111. Correlation of drug absorption with molecular charge distribution
112. Development of predictive pharmacokinetic simulation models for drug discovery
113. Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship
114. A graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates
115. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors
116. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration
117. A simple model for the prediction of blood-brain partitioning
118. Predicting blood-brain barrier permeation from three-dimensional molecular structure
119. Prediction of blood-brain partitioning using Monte Carlo simulations of molecules in water
120. Physicochemical factors that influence brain uptake
121. Epidermal permeability-penetrant structure relationships. 4. QSAR of permeant diffusion across human stratum corneum in terms of molecular weight, H-bonding and electronic charge
122. The effect of structural QSAR parameters on skin penetration
123. Three- and four-dimensional quantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
124. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6
125. Pharmacophore and three-dimensional quantitative structure-activity relationship methods for modelling cytochrome P450 active sites
126. An assessment of the reaction energetics for cytochrome P450-mediated reactions
127. Quantitative structure-pharmacokinetic relationship modelling
128. Quantitative structure-metabolism relationships (QSMR) using computational chemistry: Pattern recognition analysis and statistical prediction of phase II conjugation reactions of substituted benzoic acids in the rat
129. Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat
130. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques
131. Prediction of drug half-life values of antihistamines based on the CODES/neural network model
132. A priori prediction of tissue: Plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery
133. Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs
134. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives